Palatin Technologies Email Format

Pharmaceutical ManufacturingUnited States11-50 Employees

Palatin Technologies is a United States-based biopharmaceutical company focused on developing first-in-class medicines that modulate the melanocortin receptor system, a pathway involved in regulating appetite, energy balance, sexual desire, and the resolution of harmful inflammation. Its approved product Vyleesi is the first and only FDA-approved on-demand treatment for hypoactive sexual desire disorder in premenopausal women. The company is pursuing expanded applications of the melanocortin system to treat inflammatory and ocular conditions, with PL9643 as its leading ocular candidate for dry eye disease and additional ophthalmic programs at earlier stages; it also plans proof-of-concept studies in ulcerative colitis and kidney disease. 

Based in the United States with activity centered in Princeton, New Jersey, Palatin operates as a small-to-mid-sized biopharmaceutical company focused on developing therapies that address unmet medical needs in inflammation and ocular disease. A notable development in 2025 is a research collaboration with Boehringer Ingelheim to advance melanocortin receptor agonists for retinal diseases, illustrating ongoing partnerships to advance its pipeline.

Sign up for free to view info

Company overview Employee directory